Barclays Maintains Overweight on Claritev, Raises Price Target to $40
Barclays analyst Glen Santangelo maintains Claritev (NYSE:CTEV) with a Overweight and raises the price target from $28 to $40.
Stocks · News reference
Claritev Raises FY2026 Sales Guidance from $985.000M-$1.000B to $1.000B-$1.020B vs $993.511M Est
Claritev (NYSE:CTEV) raises FY2026 sales outlook from $985.000 million-$1.000 billion to $1.000 billion-$1.020 billion vs $993.511 million estimate.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Claritev Expands Collaboration With Marpai To Launch Pre, Post- Payment Integrity Services To Health Plans
Claritev Corporation (NYSE: CTEV), a healthcare technology, data, and insights company, today announced that Marpai, Inc. (OTCQX:MRAI) has expanded its relationship with Claritev to bring comprehensive pre- and
Wells Fargo Maintains Equal-Weight on Claritev, Raises Price Target to $30
Wells Fargo analyst Stan Berenshteyn maintains Claritev (NYSE:CTEV) with a Equal-Weight and raises the price target from $22 to $30.
Claritev Analysts Raise Their Forecasts Following Q2 Earnings
CTEV reported better-than-expected Q2 results and raised FY26 sales guidance. Analysts maintain Buy ratings with increased price targets.